Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 102184, 9 pages
http://dx.doi.org/10.1155/2014/102184
Review Article

Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology

1Gynecological Endocrinology, Pathophysiology of Menopause and Osteoporosis, IDI-IRCCS, Via Monti di Creta 104, 00167 Rome, Italy
2Laboratory of Experimental Immunology, IDI-IRCCS, 00167 Rome, Italy

Received 1 July 2014; Accepted 27 October 2014; Published 16 November 2014

Academic Editor: Kevin Sinchak

Copyright © 2014 Stefano Lello and Andrea Cavani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Estroprogestins (EPs) are combinations of estrogen and progestin with several actions on women’s health. The different pharmacological composition of EPs is responsible for different clinical effects. One of the most used low-dose EP associations is ethinylestradiol 20 mcg plus levonorgestrel 100 mcg in monophasic regimen (EE20/LNG100). This review summarizes clinical pharmacology, cycle control, and effects on lipid and glucose metabolism, coagulation, body weight/body composition, acne, and sexuality of EE20/LNG100. Overall, EE20/LNG100 combination is safe and well tolerated, and in several studies the incidence of adverse events in the treated group was comparable to that of the placebo group. Cycle control was effective and body weight/body composition did not vary among treated and untreated groups in most studies. The EE20/LNG100 combination shows mild or no effect on lipid and glucose metabolism. Lastly, EE20/LNG100 is associated with a low risk of venous thromboembolism (VTE). In conclusion, in the process of decision making for the individualization of EPs choice, EE20/LNG100 should be considered for its favorable clinical profile.